Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) EVP Sarah Condella sold 2,000 shares of the stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $70.00, for a total value of $140,000.00. Following the completion of the transaction, the executive vice president now directly owns 73,787 shares of the company’s stock, valued at approximately $5,165,090. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Sarah Condella also recently made the following trade(s):
- On Friday, March 1st, Sarah Condella sold 1,724 shares of Exact Sciences stock. The stock was sold at an average price of $59.32, for a total value of $102,267.68.
- On Tuesday, February 27th, Sarah Condella sold 1,880 shares of Exact Sciences stock. The shares were sold at an average price of $56.89, for a total transaction of $106,953.20.
- On Friday, February 23rd, Sarah Condella sold 1,021 shares of Exact Sciences stock. The stock was sold at an average price of $59.72, for a total value of $60,974.12.
- On Wednesday, February 21st, Sarah Condella sold 1,079 shares of Exact Sciences stock. The stock was sold at an average price of $61.50, for a total value of $66,358.50.
- On Thursday, February 15th, Sarah Condella sold 965 shares of Exact Sciences stock. The stock was sold at an average price of $61.43, for a total transaction of $59,279.95.
- On Tuesday, January 2nd, Sarah Condella sold 2,000 shares of Exact Sciences stock. The stock was sold at an average price of $73.50, for a total transaction of $147,000.00.
Exact Sciences Price Performance
Shares of Exact Sciences stock opened at $70.41 on Tuesday. The stock has a 50 day moving average of $61.95 and a 200 day moving average of $65.09. Exact Sciences Co. has a 12 month low of $56.05 and a 12 month high of $100.77. The firm has a market cap of $12.78 billion, a PE ratio of -61.76 and a beta of 1.25. The company has a current ratio of 2.32, a quick ratio of 2.07 and a debt-to-equity ratio of 0.74.
Institutional Trading of Exact Sciences
Hedge funds have recently made changes to their positions in the business. KB Financial Partners LLC purchased a new stake in shares of Exact Sciences during the 2nd quarter valued at about $32,000. Wolff Wiese Magana LLC raised its position in shares of Exact Sciences by 459.5% during the 4th quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock valued at $31,000 after buying an additional 340 shares in the last quarter. BluePath Capital Management LLC bought a new position in Exact Sciences during the third quarter valued at $33,000. Coppell Advisory Solutions LLC bought a new position in Exact Sciences during the second quarter valued at $46,000. Finally, ST Germain D J Co. Inc. bought a new position in Exact Sciences during the second quarter valued at $46,000. 88.82% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on EXAS shares. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Guggenheim started coverage on shares of Exact Sciences in a research report on Thursday, December 14th. They issued a “buy” rating and a $90.00 target price for the company. Canaccord Genuity Group dropped their price objective on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. TheStreet downgraded shares of Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th. Finally, Wolfe Research started coverage on Exact Sciences in a research note on Wednesday, December 13th. They set an “outperform” rating and a $95.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Exact Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $99.31.
Check Out Our Latest Research Report on Exact Sciences
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
See Also
- Five stocks we like better than Exact Sciences
- 3 Best Fintech Stocks for a Portfolio Boost
- Analysts are Bullish on These 4 Oversold Large Cap Stocks
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 5 Tech Stocks to Buy Now, Ahead of the Q1 Reports
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 5 Cheap Dividend Stocks: Which to Buy Now
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.